Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.2 USD | +0.70% | +4.51% | -36.01% |
05-15 | HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating | MT |
05-14 | Transcript : Fennec Pharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.01% | 195M | |
+8.01% | 114B | |
+9.48% | 104B | |
-1.83% | 22.57B | |
-11.63% | 22.5B | |
-10.39% | 17.95B | |
-41.90% | 16.48B | |
-14.57% | 15.82B | |
+3.73% | 13.55B | |
+27.63% | 10.99B |
- Stock Market
- Equities
- FENC Stock
- News Fennec Pharmaceuticals Inc.
- Fennec Pharmaceuticals Brief: Achieved Q1 2024 Total Net Revenues of US$25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction